Researchers discover possible weakness in deadly hospital superbug C. auris that could lead to new treatments for the ...
Explore how AI-driven multiomics is reshaping drug discovery and personalized medicine development through innovative data ...
This article examines the biological complexity of chronic pain and highlights novel therapeutic strategies including ...
For most of their lives, the two women have stayed tucked away indoors, sidelined by a rare blood disorder that makes the ...
AZoLifeSciences on MSN
Kinetic traps explain differences in GPCR drug efficacy
G-protein coupled receptors (GPCRs) are proteins triggered by ligands (protein-binding chemicals) from outside cells to transmit signals inside the cell.
G-protein coupled receptors (GPCRs) are proteins triggered by ligands (protein-binding chemicals) from outside cells to ...
Donald Trump says that Venezuela's governance will remain in the hands of senior US officials until a "proper and judicious ...
Sadettin Saran, president of Fenerbahçe, faces legal scrutiny in Turkey. Here’s a closer look at his background, business career, and role in football and basketball ...
President Donald Trump on December 18 signed an executive order to force the administration to move forward in reclassifying marijuana as a less-dangerous drug. However, that order does not legalize ...
A high-fat diet does more than overload the liver with fat. New research from MIT shows that prolonged exposure to fatty ...
As the flagship oncology journal under Sage Publishing, TAMO strives to publish research of significant value to oncology research and clinical practice. It covers clinical trials and real-world ...
IFLScience on MSN
Experimental Alzheimer’s drug could have the power to halt disease before symptoms even start
A breakthrough new Alzheimer’s disease treatment is stopping neurodegeneration in its tracks, even before symptoms appear.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results